Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease

Figure 1 Study design, exclusion criteria, and the study cohort. OLT: orthotopic liver transplantation; CMV: Cytomegalovirus.

Figure 2 Kaplan-Meier plots of patient (A) and graft (B) survival in the total population, and graft survival in the study cohort (C).

Figure 3 Kaplan-Meier plots of recurrent primary sclerosing cholangitis-free survival in patients with pre-orthotopic liver transplantation inflammatory bowel disease (blue line) and de novo inflammatory bowel disease (red line).

Figure 4 Distribution of time to recurrent primary sclerosing cholangitis in patients with cyclosporine immunosuppression (red line) vs tacrolimus immunosuppression (blue line).